Form 4: Vertex Pharmaceuticals Executive Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
EVP Edward Morrow Atkinson III sold 1,529 shares of Vertex Pharmaceuticals stock on February 14, 2025, to cover tax obligations.
Summary
- On February 14, 2025, Edward Morrow Atkinson III, EVP, Chief Technical Operations Officer of Vertex Pharmaceuticals, disposed of 1,529 shares of common stock.
- The transaction was executed to cover tax obligations.
- Following the transaction, Atkinson directly owns 27,907 shares of Vertex Pharmaceuticals common stock.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing related to a stock transaction. It doesn't inherently convey positive or negative sentiment.
Industry Context
Form 4 filings are a routine part of the US stock market, and are required by the SEC to ensure transparency of trading by corporate insiders.
Stakeholder Impact
- The transaction has a minimal impact on stakeholders as it is a routine sale of shares by an executive.
Key Dates
| Date | Description |
|---|---|
| 02/14/2025 | Date of stock transaction |
| 02/19/2025 | Date of signature on the Form 4 filing |
Keywords
VRTX, Vertex Pharmaceuticals, Executive Stock Sale, Form 4, Atkinson, Stock Transaction, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.